H eart failure (HF) is a heterogeneous disease
resulting from a number of common pathological stimuli including, but not limited to, long-standing hypertension, profound inflammation, and overactivation of neurohumoral pathways (1) . HF is a major public health problem in the United States, with a prevalence of 7 million people, and it is projected to affect more than 9 million people by 2030 (2) . Due to its heterogeneous nature, the consequences of HF are not limited to cardiac pathology.
Noncardiac comorbidities such as renal dysfunction and vascular dysfunction frequently accompany HF and further decrease patients' quality of life and clinical outcomes (3, 4) . For example, HF patients with renal dysfunction have greater chance for readmission, longer hospital stay, and worse prognosis, and vascular injury has been linked to reduced exercise capacity, leading to decreased quality of life (5, 6) .
Neurohumoral dysregulation is a hallmark feature in many cardiovascular diseases including heart failure (7) (8) (9) (10) . Specifically, overactivation of the sympathetic nervous system and the reninangiotensin-aldosterone system (RAAS) exacerbates HF symptoms and contributes to the development of comorbidities (4, 11, 12) . In fact, efficacious first-line medications for HF such as beta-blockers, mineralocorticoid receptor antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) target the sympathetic nervous system (SNS) and the RAAS overactivity. However, these medications are imperfect and have several limitations. For example, beta-blockers, mineralocorticoid receptor antagonists, and ARBs are receptor antagonists designed to compete with endogenous ligands without altering or decreasing the levels of endogenous ligands, which potentially limits their vascular protective effects (13, 14) . Distinct from receptor antagonists, ACE inhibitors reduce the endogenous production of angiotensin II (Ang II), but its use is contraindicated in patients with certain cardiorenal syndromes due to unwanted side effects (15) . Current treatments inadequately manage the diverse population of HF patients in a manner that effectively extends longevity and quality of life. Therefore, examination of novel pharmacotherapies that have the ability to protect multiple organ systems in heart failure is warranted.
H 2 S plays a key role in cardiovascular homeostasis and cardioprotection (16) (17) (18) (19) (20) . H 2 S wields a wide range of biological functions in the cardiovascular system, including mitochondria biogenesis, metabolic modulation, angiogenesis, vasodilation and blood pressure regulation, inhibition of inflammation, antioxidant, and antiapoptosis (21) 
H 2 S Attenuates RAAS Activation and Renal Dysfunction in HF reperfusion significantly reduced infarct size and circulating troponin-I levels in a murine model of myocardial ischemia-reperfusion injury (20) . In the present study, using a well-established pressure overload HF model, the efficacy of delayed therapy with JK-1 on cardiac, renal, and vascular injury and dysfunction in the setting of HF was investigated.
METHODS
EXPERIMENTAL COMPOUNDS. JK-1 and its control compound were designed and synthesized by Dr. Ming Xian et al. (20) . The optimal dose of JK-1 was selected based on the results of a previous study investigating the infarct-sparing effects of JK-1 (20) .
The structures of JK-1 and control are described in Figure 1A .
EXPERIMENTAL ANIMALS. Male C57BL/6J mice (Jackson Laboratory, Bar Harbor, Maine) were 9 weeks of age at the time of study initiation. All Li et al.
All experimental animals received humane care in accordance with National Society of Medical Research and National Institutes of Health tenets.
TRANSVERSE AORTIC CONSTRICTION PROTOCOL.
Cardiac hypertrophy and heart failure were induced through transverse aortic constriction (TAC) as previously described (19, 25, 26) . Figure S3A ).
HISTOLOGICAL ASSESSMENT. Cardiac and renal fibrosis were assessed at the 18-week endpoint as previously described (26) . To quantify global fibrosis from the Picrosirius red-stained slides, fluorescent images were obtained (original magnification Â20)
using an Olympus (model BX53-DP80, Tokyo, Japan) system and analyzed using ImageJ software (U.S. Vascular function was measured in isolated segments (3 mm in length) of thoracic aorta as previously described (27) We also evaluated vascular relaxation responses of isolated thoracic aorta to SNP. Aortas from mice that received the Control compound displayed worsened vasodilation only at concentrations of 1 and 10 nM SNP, and no significant differences were observed in maximal relaxation and EC 50 ( Figures 5D to 5F ). Taken together, these data suggest that TAC-induced HF Figure 1 . Multiple studies have previously reported that H 2 S augments the bioavailability and signaling of NO (18, (31) (32) (33) . The current study found that JK-1 treatment initiated at 3 or 10 weeks post TAC resulted in significantly elevated levels of nitrite in circulation, heart, and kidney ( Figures 7D to 7F ). In addition, significantly elevated levels of cGMP were also observed in cardiac and renal tissue at 18 weeks post Figure 3 were analyzed with 1-way ANOVA.
Circles inside bars denote sample size. Abbreviations as in Figure 1 .
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TAC in mice receiving JK-1 treatment (Supplemental Figures S4A and S4B ).
In addition, it has been reported that both H 2 S and NO are powerful antioxidants (31, 34) . Therefore, we examined the levels of oxidative stress by using 8- Figure 8E ).
DISCUSSION
It was previously shown that pharmacological H 2 S therapy ameliorates TAC-induced HF severity (19, 25, 36, 37) . However, one major limitation of those studies is that the experimental H 2 S therapies were administered prior to or right after the induction of HF other abbreviations as in Figure 1 . Severe exercise intolerance is a primary chronic symptom associated with decreased quality of life in Previously, it was reported that NO exerts sympathoinhibitory effects via attenuating the release of norepinephrine from neural terminals (54). More recently, it was discovered that elevation in oxidative stress in central nervous system resulted in systemic sympathoexcitation (40) . Given the powerful antioxidant and NO-promoting effects of H 2 S, we propose that delayed therapy with JK-1 down regulates SNS and RAAS activation. We observed that renal 
CONCLUSIONS
We have shown that delayed treatment with a novel and potent H 2 S donor, JK-1, protects multiple organs including the heart, peripheral arteries, and the kidneys against injury and dysfunctions in the setting of TAC-induced heart failure. Such protection in donor, to simultaneously protect the heart, the kidneys, the vessels, and to improved exercise performance in mice subjected to heart failure.
TRANSLATIONAL OUTLOOK: H 2 S-based therapeutics have been tested in heart failure patients and proven to be safe and bio-active. Our study identified that JK-1, a novel H 2 S donor, protects the heart against pressure overload-induced heart failure and reduces the collateral damages to the kidney and the endothelium. These findings support further clinical investigation of the efficacy of H 2 S-based therapies for treating heart failure and its comorbidities.
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